Floriano-Sánchez E, Castro-Marín M, Cárdenas-Rodríguez N, López-Silvestre JC, Zapata-Villalba MA, Campos-Salcedo JG, Estrada-Carrasco CE, Mendoza Álvarez LA, Rosas-Hernandez H, Paredes-Calva C, Reyes-Equihua JL, Sedano-Lozano A

Language: Spanish
References: 22
Page: 45-49
PDF size: 352.89 Kb.

ABSTRACT

Introduction: Prostate cancer is the second cause of death from cancer in men worldwide. Various cytochromes in this disease are being studied, but there are few reports in the literature on cytochromes CYP4F11 and CYP8A1. In the present study, the presence of CYP4F11 and CYP8A1 was investigated in prostate cancer and in benign prostatic hyperplasia.
Material and method: Thirty-two hyperplasia and thirty-two cancer samples were obtained and conditions were standardized to detect the presence of CYP4F11 and CYP8A1 in the tissues by means of immunohistochemistry.
Results: CYP4F11 and CYP8A1 were expressed in prostate cancer but not in benign prostatic hyperplasia.
Conclusions: These results suggest that CYP4F11 and CYP8A1 could be used as prognostic and/or early detection factors, by carrying out biopsies in patients suspected of having prostate cancer.

REFERENCES

1. Sona EH, D’Arcy JC, Holman Z, et al. Prostate cancer: socio-economic, geographical and private-health insurance effects on care and survival. BJU Int 2005;95:51-58.

2. Sociedad Mexicana de Cirugía. Guías clínicas en México, emisión de la Academia Mexicana de Cirugía. Sánchez González Jorge Manuel, Tena Tamayo Carlos, Díaz González Norma Juárez, Vargas Domínguez Armando, Rivera Cisneros Antonio Eugenio, Lozano Alcázar Jaime. Cir Ciruj 2004; 72(1):63-68.

3. Guess H. Benign prostatic Hyperplasia: antecedents and natural history. Epidemiol Rev 1992;14:131-153.

4. Ahmed M, Lee CT, Oesterling JE. Current trend in the epidemiology of prostatic disease: benign hyperplasia and adenocarcinoma. Boca Raton, Florida. CRC Press, 1997;589-599.

5. Fleshner N, Trachtenberg J. New developments and controversies in androgen derivation therapy for advanced prostatic carcinoma. A.U.A. Update Series 2009;03:278-279.

6. Danielson P. The cytocrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab 2002;3:561-597.

7. Wang Y, Bell JC. Gene regulation of CYP4F11 in human keratinocyte HaCaT cells. Drug Metab Dispos 2010;38:100-107.

8. Murray GI. The role of cytocrome p450 in tumour development and progression and its potential in terapy. J Pathol 2000;192:419-426.

9. Chun YJ, Kim S. Inhibitors as new promising anti-cancer agents: future therapeutic directions. Med Res Rev 2003;23:657-668.

10. Gonzalez ZM, Ensz LM, Mukhina G, et al. Manganese superoxide dismutase protects nNOS neurons from NMDA and nitric oxide-mediated neurotoxicity. J Neurosci 1998;18:2040-2055.

11. Kikuta Y, Kusunose E. A novel form of cytochrome P-450 family 4 in human polymorphonuclear leukocytes. cDNA cloningand expression of leukotriene B4 omega-hydroxylase. J Biol Chem 1993;268:9376-9380.

12. Yokoyama C, Yabuki T, Inoue H. Human gene encoding prostacyclin synthase (PTGIS): genomic organization, chromosomal localization, and promoter activity. Genomics 1996;36:296-304.

13. Agundez JA. Cytocochrome P450 gene polymorphism and cancer. Curr Drug Metab 2004;5:211-224.

14. Diane DM, David EP. Profiling Cytochrome p450 Expression in Ovarian Cancer: Identification of Prognostic Markers. Clin Cancer Res 2005;11:7369-7375.

15. Wu KK, Liou JY. Cellular and molecular biology of prostacyclin synthase. Biochem Biophys Res Commun 2005;338:45-52.

16. Pradono P, Tazawa R, Maemondo M. Gene transfer of thromboxane A (2) synthase and prostaglandin I (2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res 2002;62:63-66.

17. Wade ML, Fitzpatrick FA. Nitric oxide modulates the activity of the hemoproteins prostaglandin I2 synthase and thromboxane A2 synthase. Arch Biochem Biophys 1997;347:174-180.

18. Frigola J, Muñoz M, Clark SJ, et al. Hypermethylation of the prostacyclin synthase (PTGIS) promoter is a frequent event in colorectal cancer and associated with aneuploidy. Oncogene 2005;24:7320-7326.

19. Poole EM, Bigler J, Whitton J. Prostacyclin synthase and arachidonate 5-Lipoxygenase polymorphisms and risk of colorectal polyps. Cancer Epidemiol Biomarkers Prev 2006;15:502-508.

20. Stearman RS, Grady MC, Nana-Sinkam P, et al. Genetic and epigenetic regulation of the human prostacyclin synthase promoter in lung cancer cell lines. Mol Cancer Res 2007;5:295-308.

21. Nemenoff R, Meyer AM, Hudish TM, et al. Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator activated receptor gamma. Cancer Prev Res (Phila) 2008;1(5):349-356.

22. Kajita S, Ruebel KH, Casey MB, et al. Role of COX-2, thromboxane A2 synthase, and prostaglandin I2 synthase in papillary thyroid carcinoma growth. Mod Pathol 2005;18:221-227.